Achilles Therapeutics plc

Informe acción NasdaqCM:ACHL

Capitalización de mercado: US$44.0m

Achilles Therapeutics Dirección

Dirección controles de criterios 2/4

El CEO de Achilles Therapeutics es Iraj Ali , nombrado en Jan 2018, tiene una permanencia de 6.83 años. compensación anual total es $1.70M, compuesta por 27.3% salario y 72.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.71% de las acciones de la empresa, por valor de $1.19M. La antigüedad media del equipo directivo y de la junta directiva es de 5.4 años y 4.5 años, respectivamente.

Información clave

Iraj Ali

Chief Executive Officer (CEO)

US$1.7m

Compensación total

Porcentaje del salario del CEO27.3%
Permanencia del CEO6.8yrs
Participación del CEO2.7%
Permanencia media de la dirección5.4yrs
Promedio de permanencia en la Junta Directiva4.5yrs

Actualizaciones recientes de la dirección

Recent updates

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?

Sep 20
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Feb 26
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Nov 13
Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Jul 19
Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Mar 11
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Nov 18
Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Achilles-led group gets €4M funding for personalized cell therapy manufacturing

Jul 21

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?

Apr 13
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?

Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans

Dec 27
Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Sep 09
Here's Why We're Not Too Worried About Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Iraj Ali en comparación con los beneficios de Achilles Therapeutics?
FechaCompensación totalSalarioIngresos de la empresa
Sep 30 2024n/an/a

-US$67m

Jun 30 2024n/an/a

-US$64m

Mar 31 2024n/an/a

-US$64m

Dec 31 2023US$2mUS$463k

-US$70m

Compensación vs. Mercado: La compensación total de Iraj($USD1.70M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD646.00K).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Iraj con los resultados de la empresa.


CEO

Iraj Ali (49 yo)

6.8yrs

Permanencia

US$1,698,000

Compensación

Dr. Iraj Ali, Ph.D. serves as Chief Executive Officer at Achilles Therapeutics Plc since December 10, 2018 and served as its Interim Chief Executive Officer since January 2018 until December 10, 2018. Dr....


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Iraj Ali
CEO & Director6.8yrsUS$1.70m2.71%
$ 1.2m
Sergio Quezada
Founder & Chief Scientific Officer8.8yrssin datos1.12%
$ 494.9k
Robert Coutts
Chief Financial Officer4yrssin datos0.66%
$ 288.9k
Mark Lowdell
Founder & Member of Scientific Advisory Board8.8yrssin datossin datos
Charles Swanton
Founder & Member of Scientific Advisory Board8.8yrssin datossin datos
Lee Stern
Vice President of Investor Relations & External Communications3.9yrssin datossin datos
Daniel Carey Hood
General Counsel & Company Secretary2yrssin datossin datos
Julia Wilson
Head of Communicationsno datasin datossin datos
Tariq Ahmed
Executive Vice President of Peopleno datasin datossin datos
Edward Samuel
Executive Vice President of Technical Operationsno datasin datossin datos
Shree Patel
Executive Vice President of Supply Operationsno datasin datossin datos
James A. Taylor
Chief Business Officer2.8yrssin datossin datos

5.4yrs

Permanencia media

50.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ACHL es experimentado (5.4 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Iraj Ali
CEO & Director8.7yrsUS$1.70m2.71%
$ 1.2m
Mark Lowdell
Founder & Member of Scientific Advisory Boardless than a yearsin datossin datos
Charles Swanton
Founder & Member of Scientific Advisory Boardless than a yearsin datossin datos
Edwin Moses
Independent Chairman of the Board5.9yrsUS$379.00k0.55%
$ 242.4k
Carsten Boess
Independent Non-Executive Director4.6yrsUS$176.00k0%
$ 0
Markwin Velders
Member of Scientific Advisory Board3.5yrssin datossin datos
Scott Antonia
Member of Scientific Advisory Board4.5yrssin datossin datos
Michael Giordano
Independent Non-Executive Director6.2yrsUS$189.00k0.11%
$ 50.0k
Karl Peggs
Founder & Member of Scientific Advisory Boardless than a yearsin datos1.36%
$ 600.2k
Elizabeth Jaffee
Member of Scientific Advisory Board4.5yrssin datossin datos
Christopher Klebanoff
Member of Scientific Advisory Board4.5yrssin datossin datos
Alena Gros
Member of Scientific Advisory Board2.8yrssin datossin datos

4.5yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: La junta directiva de ACHL se considera experimentada (4.5 años de antigüedad promedio).